+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Checkpoint Inhibitors"

From
From
From
From
From
From
USA Solid Tumor Therapeutics Market Outlook to 2028 - Product Thumbnail Image

USA Solid Tumor Therapeutics Market Outlook to 2028

  • Report
  • October 2023
  • 85 Pages
  • United States
From
From
Checkpoint Inhibitors Global Market Report 2024 - Product Thumbnail Image

Checkpoint Inhibitors Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
Drugs for Immunotherapy Global Market Report 2024 - Product Thumbnail Image

Drugs for Immunotherapy Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
From
Checkpoint Inhibitors - Competitive landscape, 2023 - Product Thumbnail Image

Checkpoint Inhibitors - Competitive landscape, 2023

  • Report
  • April 2023
  • 350 Pages
  • Global
From
Oncolytic Virus - Competitive Landscape, 2022 - Product Thumbnail Image

Oncolytic Virus - Competitive Landscape, 2022

  • Report
  • October 2022
  • 300 Pages
  • Global
From
From
From
Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2024 - Product Thumbnail Image

Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
Loading Indicator

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more